---
layout: default
title: Deferasirox
parent: 僅模型預測 (L5)
nav_order: 66
evidence_level: L5
indication_count: 5
---

# Deferasirox
{: .fs-9 }

證據等級: **L5** | 預測適應症: **5** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

The `txgnn-pipeline` skill is focused on pipeline management and doesn't override the report generation instructions in my system prompt. I'll proceed to generate the evaluation report based on the Evidence Pack.

---

# DEFERASIROX: Evaluation Pending — No TxGNN Predictions Available

## One-Sentence Summary

DEFERASIROX is an oral iron chelator used to treat chronic iron overload caused by blood transfusions and related conditions.
The current Evidence Pack contains **no TxGNN-predicted indications**, and critical data including mechanism of action, safety warnings, and regulatory authorizations are absent.
A full repurposing evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in Evidence Pack |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | — |
| Evidence Level | — (No predictions to evaluate) |
| Italy Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN-predicted indication is present in this Evidence Pack, so a mechanism-based rationale for a specific new indication cannot be provided at this time.

DEFERASIROX is broadly recognized as a tridentate iron chelator with high selectivity for ferric iron (Fe³⁺), forming stable complexes that are excreted primarily via feces. It is an established treatment for chronic transfusional iron overload in diseases such as beta-thalassemia major and myelodysplastic syndromes. Mechanism of action data (MOA) is flagged as a data gap in this pack and must be retrieved from DrugBank before any mechanism-level analysis can proceed.

From a scientific standpoint, iron dysregulation has been implicated in a range of conditions beyond iron overload — including certain malignancies, ferroptosis-related pathways, and neurodegenerative diseases — making DEFERASIROX an interesting repurposing candidate in principle. However, without TxGNN model output, any such reasoning remains speculative and should not be cited as evidence.

---

## Clinical Trial Evidence

No TxGNN-predicted indication is available, so clinical trial evidence cannot be scoped or retrieved at this time.

Once a target indication is identified via TxGNN, relevant trials should be retrieved from [ClinicalTrials.gov](https://clinicaltrials.gov/).

---

## Literature Evidence

No TxGNN-predicted indication is available, so literature evidence cannot be scoped or retrieved at this time.

Once a target indication is identified, relevant publications should be retrieved from [PubMed](https://pubmed.ncbi.nlm.nih.gov/).

---

## Safety Considerations

Please refer to the package insert for safety information.

> Note: TFDA package insert was queried (2026-03-29) and a result was found (`result_count: 1`), but warnings and contraindications were not parsed into the Evidence Pack. This is classified as a **Blocking** data gap (DG001) and must be resolved before safety review can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for DEFERASIROX is structurally incomplete — there are no TxGNN-predicted indications and no safety or regulatory data. A repurposing evaluation cannot move forward until the blocking data gaps are resolved.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Parse TFDA package insert (already retrieved, `result_count: 1`) to extract warnings and contraindications
- **[High — DG002]** Retrieve mechanism of action (MOA) from DrugBank (DB01609)
- **[Critical]** Run TxGNN model to generate predicted indications for DEFERASIROX
- Confirm regulatory status in target markets (Italy / Taiwan) and retrieve authorization records if any exist
- Re-run Evidence Pack generation pipeline once all inputs are available to produce a complete v5 pack
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

